Androgens and breast cancer risk
- PMID: 22394304
- DOI: 10.3109/09513590.2012.651925
Androgens and breast cancer risk
Abstract
Transdermal testosterone supplementation is a treatment option for postmenopausal women with distressful decreased libido. Side effects are minor, but there is a long-term safety concern with respect to breast cancer, as women with high testosterone serum levels appear to be at a significantly increased risk to have or to develop breast cancer within a few years. Epidemiological studies of sufficient duration to study long-term effects of testosterone supplementation are limited, both in number and in methodological quality and are, therefore, inconclusive. Preclinical studies do not provide evidence for an androgen receptor-mediated stimulating effect of androgens on breast epithelium. However, one biologically plausible possibility, which cannot be ruled out, is that exogenous androgens become mitogenic after aromatization into bioactive oestradiol, either in peripheral fat or within the breast or even within small occult tumours. The evidence available so far makes counselling women interested in testosterone supplementation for distressful low sexual desire, more of an art than science.
Similar articles
-
Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk?Fertil Steril. 2008 Jul;90(1):129-40. doi: 10.1016/j.fertnstert.2007.05.057. Epub 2007 Nov 26. Fertil Steril. 2008. PMID: 18023435 Review.
-
The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.Maturitas. 2009 Jul 20;63(3):213-9. doi: 10.1016/j.maturitas.2009.04.008. Epub 2009 May 31. Maturitas. 2009. PMID: 19487090 Review.
-
Testosterone and the breast.Menopause Int. 2008 Sep;14(3):117-22. doi: 10.1258/mi.2008.008015. Menopause Int. 2008. PMID: 18714077 Review.
-
Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy.Maturitas. 2008 Mar 20;59(3):209-18. doi: 10.1016/j.maturitas.2008.01.005. Epub 2008 Mar 14. Maturitas. 2008. PMID: 18343056 Review.
-
The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society.Menopause. 2005 Sep-Oct;12(5):496-511; quiz 649. doi: 10.1097/01.gme.0000177709.65944.b0. Epub 2005 Sep 1. Menopause. 2005. PMID: 16145303 Review.
Cited by
-
Transdermal Testosterone in Female Hypoactive Sexual Desire Disorder: A Rapid Qualitative Systematic Review Using Grading of Recommendations Assessment, Development and Evaluation.Cureus. 2018 Mar 31;10(3):e2401. doi: 10.7759/cureus.2401. Cureus. 2018. PMID: 29868302 Free PMC article. Review.
-
Male DCIS diagnosed after use of over-the-counter hormonal supplement.Int J Surg Case Rep. 2019;57:60-62. doi: 10.1016/j.ijscr.2019.02.028. Epub 2019 Feb 26. Int J Surg Case Rep. 2019. PMID: 30903856 Free PMC article.
-
Association between testosterone and cancers risk in women: a two-sample Mendelian randomization study.Discov Oncol. 2023 Nov 4;14(1):198. doi: 10.1007/s12672-023-00811-2. Discov Oncol. 2023. PMID: 37924384 Free PMC article.
-
Risks of testosterone replacement therapy in men.Indian J Urol. 2014 Jan;30(1):2-7. doi: 10.4103/0970-1591.124197. Indian J Urol. 2014. PMID: 24497673 Free PMC article. Review.
-
Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors.Clinics (Sao Paulo). 2014;69(4):294-303. doi: 10.6061/clinics/2014(04)11. Clinics (Sao Paulo). 2014. PMID: 24714838 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical